api – Katalyst Wealth

[Stock idea]: Aarti Drugs – ₹600 cr capex done, RoCE at 11.5%. Aarti Drugs’ real test starts now

October 8, 2026

Aarti Drugs’ Q1 profit before tax rose 35%, but almost all of the growth came from price. Realizations rose 16–17% year-on-year while volumes grew just 3.5%, helped by raw-material shortages linked to the West Asia conflict. Management says prices have already started easing. The question for the next few quarters is whether the capacity the company has spent ₹600 cr building can take over from price. Our notes from the presentation and the concall are below, but before that: Spread…

Strong Results: Asahi Songwon and Ugar Sugar Works this week

May 15, 2025

The results season is on and the companies have been announcing quarter and year ending Mar’25 results. We found results by Asahi Songwon and Ugar Sugar Works interesting and here are the details: Before that, in the month of April 2025 and May 2025, we have released the following new stock recommendations: On 11th Apr’25, we released a new recommendation under “(opens in new tab)Insider Bets” subscription. You can read about it by (opens in new tab)clicking HERE On 16th Apr’25, we released a new Special situation opportunity…

[Stock notes] – Natural Capsules…From Gelatin capsules to APIs

December 29, 2023

Hello Sir, Hope you are doing well. Recently, I came across Natural Capsules Ltd. It is the 2nd largest Indian manufacturer for gelatin capsules and now foraying into API manufacturing. API division is yet to start contributing to sales. Source: Natural Capsules Presentation What interesting is, even though the total demand for such APIs seems small, the company claims that it will be the only manufacturer for 2 out of 3 APIs in India and 1 of the 2 for…

[Stock idea] – Aarti Drugs…notes for a leading pharma API company

March 18, 2023

Hello Sir,Hope you are doing well.Remember, in late 2020, Pharma API companies were the darling of the market. Most are down 50-60% from their highs and in downtrend. Their high margins of FY 20-21 didn’t sustain.It seems like earnings may have bottomed out and some of them seem to be available at reasonable valuations from a 3-4 years investment perspective.Aarti Drugs is a major player in the pharma API segment and has been a very lucky stock for us.We have recommended…